Angus Grant - 04 Mar 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Business Development
Signature
/s/ Dov Bergwerk as attorney-in-fact for Angus Grant
Issuer symbol
TEVA
Transactions as of
04 Mar 2024
Net transactions value
$0
Form type
4
Filing time
05 Mar 2024, 16:30:16 UTC
Previous filing
10 Aug 2023
Next filing
13 Aug 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +52,083 $0.000000 52,083 04 Mar 2024 Ordinary Shares 52,083 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on March 4, 2024, with 13,020 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 13,023 vesting on March 4, 2028.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.